[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355135-105":59,"doc-detail-355135-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","impact-of-synbiotics-on-disease-activity-in-systemic-lupus-erythematosus-results-from-a-randomized-clinical-trial","Impact of synbiotics on disease activity in systemic lupus erythematosus: Results from a randomized clinical trial","","Systemic lupus erythematosus (SLE) is an autoimmune disease in which inflammatory cytokines drive and sustain ongoing inflammation across organs. A randomized, double-blind, placebo-controlled trial evaluated whether synbiotics can modulate interleukin-17A (IL-17A), disease activity, and related inflammatory factors. Fifty patients received standard therapy plus synbiotics or standard therapy alone for two months. The synbiotics group showed significant reductions in IL-17A protein and mRNA levels and in SLE Disease Activity Index 2000 scores versus baseline, while placebo produced no significant changes. Synbiotic supplementation may serve as an adjunct option for SLE management, requiring further mechanistic studies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/impact-of-synbiotics-on-disease-activity-in-systemic-lupus-erythematosus-results-from-a-randomized-clinical-trial/355135/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/impact-of-synbiotics-on-disease-activity-in-systemic-lupus-erythematosus-results-from-a-randomized-clinical-trial/355135.png","ImageObject",300,407,{"name":92,"@type":93},"eBook King","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":56},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main aim of the randomized clinical trial?","Question",{"text":112,"@type":113},"To assess how synbiotics affect IL-17A levels, disease activity, and inflammatory factors in patients with SLE.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were participants assigned and what did they receive?",{"text":117,"@type":113},"Fifty patients were randomly assigned to standard therapy plus synbiotics or standard therapy alone for two months, in a double-blind, placebo-controlled design.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the key results regarding IL-17A and disease activity?",{"text":121,"@type":113},"The synbiotics group showed significant decreases in IL-17A protein and mRNA levels and a reduction in SLE DAI 2000 scores after intervention compared with baseline; the placebo group showed no significant changes.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},355135,1790380231,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":56,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962088006270,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Received: 11 July 2024 Revised: 11 September 2024 Accepted: 25 September 2024  \nDOI: 10.1111/1750-3841.17460  \nORIGINAL ARTICLE  \nH e alth, Nutrition, a nd Food  \nImpact of synbiotics on disease activity in systemic lupus erythematosus: Results from a randomized clinical trial  \nZahra Mirfeizi1  Mahmoud Mahmoudi2, 3  Mohammad Hassan jokar1  Maryam Sahebari1  Elmira Noori2  Hasan Mehrad-Majd4  Mehdi Barati5  Arezoo Faridzadeh2, 3   \n1 Rheumatology Department, Rheumatic Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran  \n2 Immunology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran  \n3 Department of Immunology and Allergy, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran  \n4 Clinical Research Development Unit, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran  \n5 Department of Laboratory Sciences, School of Paramedicine, North Khorasan University of Medical Sciences, Bojnurd, Iran  \nCorrespondence  \nArezoo Faridzadeh, Department of Immunology, Emam Reza Hospital, Mashhad, Iran.  \nEmail: [arezoofaridzadeh@gmail.com](arezoofaridzadeh@gmail.com)  \nMehdi Barati, Department of Laboratory Sciences, School of Paramedicine, North Khorasan University of Medical Sciences, Bojnurd, Iran. [Email:](Email: mehdi.barati10@yahoo.com)[ mehdi.barati10@yahoo.com](Email: mehdi.barati10@yahoo.com)  \nFunding information  \nMashhad University of Medical Sciences, Grant/Award Number:  \nIR.MUMS.MEDICAL.REC.1399.577  \nAbstract: Systemic lupus erythematosus (SLE) is an autoimmune disease that affects various organs in the body. In SLE, inflammatory cytokines play a crucial role in initiating and sustaining the inflammatory process. Synbiotics may help modulate these inflammatory cytokines. This randomized, double-blind, placebo-controlled clinical trial aimed to assess the impact of synbiotics intervention on interleukin-17A (IL-17A) levels, disease activity, and inflammatory factors in patients with SLE. Fifty SLE patients were randomly assigned to receive either standard therapy plus synbiotics (consisting of Streptococcus thermophilus, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus rhamnosus, Lactobacillus salivarius, Lactobacillus reuteri, Bifidobacterium lactis, Bifidobacterium longum, Bifidobacterium bifidum, and the prebiotic fructooligosaccharides) or standard therapy alone for 2 months. The results demonstrated a significant reduction in both protein and mRNA levels of IL-17A, as well as in the Systemic Lupus Erythematosus Disease Activity Index 2000 score, within the synbiotics group after the intervention compared to baseline. In contrast, the placebo group did not experience significant changes in IL-17A levels or disease activity. Synbiotic supplementation shows potential as an adjunctive therapeutic approach for SLE management; however, further research is needed to elucidate its underlying mechanisms.  \nKEYWORDS  \nBifidobacterium , interleukin-17A, Lactobacillus , SLE, SLE DAI  \nPractical Application: This study explores the use of synbiotics as a supplementary treatment for systemic lupus erythematosus, which is typically managed with immunosuppressive therapies.  \nJ. Food Sci. 2024;89:9835–[9845.](9845. wileyonlinelibrary.com/journal/jfds)[ wileyonlinelibrary.com/journal/jfds](9845. wileyonlinelibrary.com/journal/jfds) © 2024 Institute of Food Technologists.  9835  \n9836  \n1  INTRODUCTION  \nSystemic lupus erythematosus (SLE) is a chronic autoimmune disease in which the immune system attacks various organs and tissues in the body (Crispín & Tsokos, 2010) . While the exact cause of SLE remains unknown, it is thought to involve a combination of genetic, environmental, and immunological factors. The dysregulation of T-helper 17 (Th17) cells has been implicated in the pathogenesis of SLE (Crispín & Tsokos, 2010) . Genetic and epigenetic changes have been found to influence the immunobiology of lupus through environmental factors ","cbCaimij1iV9JEIQ","https://ap.wps.com/l/cbCaimij1iV9JEIQ","pdf",602674,11,"English","# Introduction\n## Disease background and objectives\n## Challenges of current SLE treatment\n## Nutritional interventions and microbiome-based therapies (probiotics, prebiotics, synbiotics)","[{\"question\":\"What was the main aim of the randomized clinical trial?\",\"answer\":\"To assess how synbiotics affect IL-17A levels, disease activity, and inflammatory factors in patients with SLE.\"},{\"question\":\"How were participants assigned and what did they receive?\",\"answer\":\"Fifty patients were randomly assigned to standard therapy plus synbiotics or standard therapy alone for two months, in a double-blind, placebo-controlled design.\"},{\"question\":\"What were the key results regarding IL-17A and disease activity?\",\"answer\":\"The synbiotics group showed significant decreases in IL-17A protein and mRNA levels and a reduction in SLE DAI 2000 scores after intervention compared with baseline; the placebo group showed no significant changes.\"}]","Impact of synbiotics on disease activity in systemic lupus erythematosus: Results from a randomized clinical trial | PDF",1790116274,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0f3f4038cd9773dc5ddeb27abd0639f5.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d95dd154d56c7e6f5b082db3d1243eda.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/852092def8564cb57893e1e59b021956.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d590175a3f625d0b393d8df2b6e1e356.webp",980,1287]